Sight Sciences (NASDAQ: SGHT) revenue
Sight Sciences reported revenue of $77.4m for fiscal 2025, 3.1% less than in fiscal 2024 ($79.9m). Since fiscal 2020 its revenue has grown by 179.9%, an average growth of 22.9% a year.
Sight Sciences's revenue has fallen for 2 years in a row, and its best year of the last 6 was fiscal 2023. The biggest drop was in fiscal 2025, −3.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $77.4m | −3.1% | −$37.1m | −48.0% |
| 2024 | $79.9m | −1.5% | −$50.5m | −63.3% |
| 2023 | $81.1m | +13.6% | −$57.3m | −70.7% |
| 2022 | $71.3m | +45.7% | −$84.0m | −117.7% |
| 2021 | $49.0m | +77.1% | −$51.5m | −105.2% |
| 2020 | $27.6m | — | −$32.2m | −116.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Sight Sciences revenue compared with its sector
By revenue for its latest fiscal year, Sight Sciences ranks 305th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Sight Sciences, −3.1%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 303rd | Simulations Plus | $79.2m | 13.1% |
| 304th | Pro-DEX | $77.5m | 16.5% |
| 305th | Sight Sciences | $77.4m | −3.1% |
| 306th | CytomX Therapeutics | $76.2m | −44.8% |
| 307th | AbCellera Biologics | $75.1m | 160.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Sight Sciences
- How much revenue did Sight Sciences make in fiscal 2025?
- Sight Sciences reported revenue of $77.4m for fiscal 2025, compared with $79.9m in fiscal 2024.
- How much has the revenue of Sight Sciences grown?
- Between fiscal 2020 and fiscal 2025 it went from $27.6m to $77.4m: 179.9% more, an average growth of 22.9% a year.
- What was the best year for revenue at Sight Sciences?
- Of its last 6 fiscal years, fiscal 2023, with $81.1m.
- Where does Sight Sciences rank in its sector by revenue?
- It ranks 305th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Sight Sciences come from?
- From the annual report (Form 10-K) that Sight Sciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Sight Sciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Sight Sciences: the Sight Sciences page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.